Form 4: Director Paul Graves Acquires Charles River Labs Stock
Statement of Changes in Beneficial Ownership
Director Paul W. Graves acquired 1,438 shares of common stock in Charles River Laboratories International, Inc. on May 8, 2026.
Summary
- Director Paul W. Graves acquired 1,438 shares of common stock in Charles River Laboratories International, Inc. on May 8, 2026, at a price of $177.62 per share.
- Following this transaction, Mr. Graves beneficially owns 2,384 shares of common stock.
- The acquired shares were part of a transaction made pursuant to a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider transaction under a pre-arranged plan, with no immediate indication of significant positive or negative company performance.
Positives
- Director acquisition of shares can signal confidence in the company's future prospects.
- The transaction was made under a Rule 10b5-1(c) plan, indicating pre-planned and potentially non-insider trading related activity.
Future Outlook
The filing mentions that unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders, indicating a future event related to equity compensation.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. Director purchases, especially under Rule 10b5-1(c) plans, are common and generally viewed neutrally unless they represent a significant portion of the insider's holdings or are part of a pattern.
Stakeholder Impact
- Shareholders: The acquisition by a director may be viewed positively as a sign of confidence, but the transaction size is relatively small in the context of the company's overall market capitalization.
Next Steps
- Vesting of unvested restricted stock units on or before May 8, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/08/2026 | Transaction Date for acquisition of common stock. |
| 05/12/2026 | Date of Report (Signature Date). |
| 05/08/2027 | Vesting date for unvested restricted stock units (earlier of this date or the business day prior to the Company's next annual meeting). |
Keywords
Form 4, SEC Filing, Insider Trading, Beneficial Ownership, Charles River Laboratories, Paul Graves, Common Stock, Rule 10b5-1(c)
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.